You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCalcium Acetate
Accession NumberDB00258  (APRD00839)
Typesmall molecule
Groupsapproved
Description

The chemical compound calcium acetate is the calcium salt of acetic acid. An older name is acetate of lime. The anhydrous form is very hygroscopic, therefore the monohydrate is the common form. [Wikipedia]

Structure
Thumb
Synonyms
SynonymLanguageCode
Acetate OF limeNot AvailableNot Available
Brown acetate of limeNot AvailableNot Available
Ca(oac)2Not AvailableNot Available
calcium ethanoateNot AvailableNot Available
calcium(II) acetateNot AvailableNot Available
Gray acetate of limeNot AvailableNot Available
Lime acetateNot AvailableNot Available
Lime pyroligniteNot AvailableNot Available
SaltsNot Available
Brand names
NameCompany
ELIPHOSNot Available
PhosLoNabi Biopharmaceuticals
PhoslyraNot Available
TeltozanNot Available
Brand mixtures
Brand NameIngredients
Anti StressCalcium Acetate + Folic Acid + Magnesium Chloride + Menadione Sodium Bisulfite + Potassium (Potassium Bicarbonate) + Pyridoxine Hydrochloride + Sodium Acetate + Sodium Chloride + Vitamin a + Vitamin B12 + Vitamin C + Vitamin D3 + Vitamin E
Electrolyte BoosterBiotin + Calcium Acetate + Folic Acid + Magnesium Chloride + Menadione Sodium Bisulfite + Potassium Chloride + Sodium Acetate + Sodium Bicarbonate + Sodium Chloride + Sodium Diacetate + Vitamin a (Vitamin a Acetate) + Vitamin B12 + Vitamin B2 (Riboflavin) + Vitamin B6 (Pyridoxine Hydrochloride) + Vitamin C (Ascorbic Acid) + Vitamin D3 (Cholecalciferol) + Vitamin E (Dl-Alpha Tocopheryl Acetate)
Electrolytes PlusCalcium Acetate + Calcium D-Pantothenate + Choline Bitartrate + Folic Acid + Magnesium Chloride + Menadione (Menadione Sodium Bisulfite) + Nicotinamide + Potassium Chloride + Sodium Acetate + Sodium Chloride + Sodium Diacetate + Vitamin a Acetate + Vitamin B12 + Vitamin B2 + Vitamin D3 + Vitamin E
ElectroviteCalcium Acetate + Calcium Chloride + Folic Acid + Magnesium Acetate + Menadione Sodium Bisulfite + Potassium Chloride + Sodium Acetate + Sodium Chloride + Sodium Diacetate + Vitamin a + Vitamin B12 + Vitamin B6 + Vitamin C + Vitamin D3 + Vitamin E
HyperlyteMulti-Electrolyte Concentrate) (Calcium Acetate + Magnesium Acetate + Potassium Acetate + Potassium Chloride + Sodium Acetate + Sodium Gluconate
JugelectCalcium Acetate + Calcium Citrate + Magnesium Acetate + Magnesium Citrate + Potassium Chloride + Sodium Chloride
LypholyteCalcium Acetate + Magnesium Acetate + Potassium Acetate + Potassium Chloride + Sodium Acetate + Sodium Gluconate
Medi-Kool PakAluminum Sulfate + Arnica + Boric Acid + Calcium Acetate + Camphor + Menthol + Methyl Salicylate + Tannic Acid
Mineralytes PlusCalcium Acetate + Calcium D-Pantothenate + Choline Bitartrate + Dl-Alpha Tocopheryl Acetate + Folic Acid + Magnesium Chloride + Menadione (Menadione Sodium Bisulfite) + Nicotinamide + Potassium Chloride + Sodium Acetate + Sodium Chloride + Sodium Diacetate + Vitamin a Acetate + Vitamin B12 + Vitamin B2 + Vitamin D3
Parvit IICalcium Acetate + Folic Acid + Magnesium Chloride + Menadione Sodium Bisulfite (Vitamin K3) + Potassium (Potassium Bicarbonate) + Sodium (Sodium Acetate, Sodium Diacetate, Sodium Chloride) + Vitamin a + Vitamin B12 + Vitamin B6 (Pyridoxine Hydrochloride) + Vitamin C (Vitamin C) + Vitamin D3 + Vitamin E
RenodoronCalcium Acetate + Silicon Dioxide
Super ElectrolyteCalcium Acetate + Calcium D-Pantothenate + Choline Bitartrate + Folic Acid + Magnesium Chloride + Menadione (Menadione Sodium Bisulfite) + Nicotinamide + Potassium Chloride + Sodium Acetate + Sodium Chloride + Sodium Diacetate + Vitamin a (Vitamin a Acetate) + Vitamin B12 + Vitamin B2 (Riboflavin) + Vitamin D3 (Cholecalciferol) + Vitamin E (Dl-Alpha Tocopheryl Acetate)
Tym-PlexCalcium Acetate + Calcium Sulfide Crude + Echinacea Angustifolia + Phosphoric Acid + Phosphorus
Vitadol PlusCalcium Acetate + Folic Acid + Magnesium Chloride + Menadione Sodium Bisulfite + Potassium Bicarbonate + Sodium Acetate + Sodium Chloride + Sodium Diacetate + Vitamin a + Vitamin B12 + Vitamin B6 + Vitamin C + Vitamin D3 + Vitamin E
Categories
CAS number62-54-4
WeightAverage: 158.166
Monoisotopic: 157.989199835
Chemical FormulaC4H6CaO4
InChI KeyVSGNNIFQASZAOI-UHFFFAOYSA-L
InChI
InChI=1S/2C2H4O2.Ca/c2*1-2(3)4;/h2*1H3,(H,3,4);/q;;+2/p-2
IUPAC Name
calcium diacetate
SMILES
[Ca++].CC([O-])=O.CC([O-])=O
Mass SpecNot Available
Taxonomy
KingdomNot Available
SuperclassNot Available
ClassNot Available
SubclassNot Available
Direct parentNot Available
Alternative parentsNot Available
SubstituentsNot Available
Classification descriptionNot Available
Pharmacology
IndicationCalcium acetate is one of a number of calcium salts used to treat hyperphosphatemia (too much phosphate in the blood) in patients with kidney disease.
PharmacodynamicsPatients with advanced renal insufficiency (creatinine clearance less than 30 ml/min) exhibit phosphate retention and some degree of hyperphosphatemia. The retention of phosphate plays a pivotal role in causing secondary hyperparathyroidism associated with osteodystrophy, and soft-tissue calcification. The mechanism by which phosphate retention leads to hyperparathyroidism is not clearly delineated. Therapeutic efforts directed toward the control of hyperphosphatemia include reduction in the dietary intake of phosphate, inhibition of absorption of phosphate in the intestine with phosphate binders, and removal of phosphate from the body by more efficient methods of dialysis. The rate of removal of phosphate by dietary manipulation or by dialysis is insufficient. Dialysis patients absorb 40% to 80% of dietary phosphorus. Therefore, the fraction of dietary phosphate absorbed from the diet needs to be reduced by using phosphate binders in most renal failure patients on maintenance dialysis. Calcium acetate when taken with meals combines with dietary phosphate to form insoluble calcium phosphate which is excreted in the feces. Maintenance of serum phosphorus below 6.0 mg/dl is generally considered as a clinically acceptable outcome of treatment with phosphate binders. Calcium acetate is highly soluble at neutral pH, making the calcium readily available for binding to phosphate in the proximal small intestine.
Mechanism of actionCalcium acetate and other calcium salts are phosphate binders. They work by binding with the phosphate in the food you eat, so that it is eliminated from the body without being absorbed.
Absorption40% is absorbed in the fasting state and approximately 30% is absorbed in the nonfasting state following oral administration.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism
Route of eliminationCalcium acetate when taken with meals, combines with dietary phosphate to form insoluble calcium phosphate which is excreted in the feces.
Half lifeNot Available
ClearanceNot Available
ToxicityOral, rat: LD50 = 4280 mg/kg. Symptoms of overdose include mild hypercalcemia (constipation; loss of appetite; nausea and vomiting), and severe hypercalcemia (confusion; full or partial loss of consciousness; incoherent speech).
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
Property Value Probability
Human Intestinal Absorption + 0.705
Blood Brain Barrier + 0.9601
Caco-2 permeable - 0.5258
P-glycoprotein substrate Non-substrate 0.8366
P-glycoprotein inhibitor I Non-inhibitor 0.9806
P-glycoprotein inhibitor II Non-inhibitor 0.9866
Renal organic cation transporter Non-inhibitor 0.9609
CYP450 2C9 substrate Non-substrate 0.8335
CYP450 2D6 substrate Non-substrate 0.9164
CYP450 3A4 substrate Non-substrate 0.7384
CYP450 1A2 substrate Non-inhibitor 0.9381
CYP450 2C9 substrate Non-inhibitor 0.9273
CYP450 2D6 substrate Non-inhibitor 0.9462
CYP450 2C19 substrate Non-inhibitor 0.9608
CYP450 3A4 substrate Non-inhibitor 0.9627
CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.985
Ames test Non AMES toxic 0.9042
Carcinogenicity Carcinogens 0.5617
Biodegradation Ready biodegradable 0.9734
Rat acute toxicity 1.8756 LD50, mol/kg Not applicable
hERG inhibition (predictor I) Weak inhibitor 0.9812
hERG inhibition (predictor II) Non-inhibitor 0.9888
Pharmacoeconomics
Manufacturers
  • Roxane laboratories inc
  • Fresenius medical care north america
  • Cypress pharmaceutical inc
Packagers
Dosage forms
FormRouteStrength
LiquidOral
Solution / dropsOral
TabletOral
Prices
Unit descriptionCostUnit
PhosLo 667 mg capsule1.05USDcapsule
Phoslo 667 mg tablet0.41USDtablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
CountryPatent NumberApprovedExpires (estimated)
United States65766652001-04-032021-04-03
Properties
Statesolid
Experimental Properties
PropertyValueSource
melting point> 160 °CNot Available
Predicted Properties
PropertyValueSource
water solubility1.47e+02 g/lALOGPS
logP0.24ALOGPS
logP-0.22ChemAxon
logS-0.03ALOGPS
pKa (strongest acidic)4.54ChemAxon
physiological charge-1ChemAxon
hydrogen acceptor count2ChemAxon
hydrogen donor count0ChemAxon
polar surface area40.13ChemAxon
rotatable bond count0ChemAxon
refractivity23.48ChemAxon
polarizability4.96ChemAxon
number of rings0ChemAxon
bioavailability1ChemAxon
rule of fiveYesChemAxon
Ghose filterNoChemAxon
Veber's ruleNoChemAxon
MDDR-like ruleNoChemAxon
Spectra
SpectraNot Available
References
Synthesis Reference

Alan B. Gancy, “Process of making calcium acetate deicing agents and product.” U.S. Patent US4444672, issued November, 1946.

US4444672
General ReferenceNot Available
External Links
ResourceLink
KEGG DrugD00931
PubChem Compound6116
PubChem Substance46507985
ChemSpider5890
ChEBI3310
ChEMBLCHEMBL1200800
PharmGKBPA164746897
Drug Product Database1982591
Drugs.comhttp://www.drugs.com/cdi/calcium-acetate.html
WikipediaCalcium_Acetate
ATC CodesA12AA12
AHFS Codes
  • 40:18.19
  • 92:02.00*
PDB EntriesNot Available
FDA labelshow(25.6 KB)
MSDSshow(72.9 KB)
Interactions
Drug Interactions
Drug
AlendronateCalcium Salts may decrease the serum concentration of Bisphosphonate Derivatives such as alendronate. Avoid administration of oral calcium supplements within 30 minutes after alendronate.
Calcium carbonateCalcium salts may enhance the adverse/toxic effect of calcium acetate. Concurrent use of other calcium salts with calcium acetate should be avoided when possible. This combination is particularly dangerous in patients with other risk factors for hypercalcemia, such as those with end-stage renal disease.
Calcium ChlorideCalcium salts may enhance the adverse/toxic effect of calcium acetate. Concurrent use of other calcium salts with calcium acetate should be avoided when possible. This combination is particularly dangerous in patients with other risk factors for hypercalcemia, such as those with end-stage renal disease.
CeftriaxoneCalcium Salts (Intravenous) may enhance the adverse/toxic effect of Ceftriaxone. Ceftriaxone binds to calcium forming an insoluble precipitate. Concurrent or sequential use (within 48 hours) of ceftriaxone with calcium-containing solutions is contraindicated in neonates (28 days of age or younger). In other patients, these solutions can be used sequentially if the infusion lines are flushed with a compatible fluid between ceftriaxone and calcium-containing solution infusion.
CiprofloxacinCalcium salts such as calcium acetate may decrease the absorption of quinolone antibiotics such as ciprofloxacin. Of concern only with oral administration of both agents. Interactions can be minimized by administering oral quinolone at least 2 hours before, or 6 hours after, the dose of an oral calcium supplement. Monitor for decreased therapeutic effects of oral quinolones if administered with oral calcium supplements.
ClodronateCalcium Salts may decrease the serum concentration of Bisphosphonate Derivatives such as clodronate. Avoid administration of oral calcium supplements within 2 hours before or after tiludronate/clodronate/etidronate.
DemeclocyclineCalcium salts such as calcium acetate may decrease the serum concentration of tetracycline derivatives such as demeoclocycline. In general, the coadministration of oral calcium salts and oral tetracycline derivatives should be avoided. Interactions may be able to be minimized by administering oral calcium preparations several hours before or after the dose of the oral tetracycline derivatives. Even with dose separation, therapy may still be compromised. Monitor for decreased therapeutic effect of oral tetracycline derivatives.
DoxycyclineCalcium salts such as calcium acetate may decrease the serum concentration of tetracycline derivatives such as doxycycline. In general, the coadministration of oral calcium salts and oral tetracycline derivatives should be avoided. Interactions may be able to be minimized by administering oral calcium preparations several hours before or after the dose of the oral tetracycline derivatives. Even with dose separation, therapy may still be compromised. Monitor for decreased therapeutic effect of oral tetracycline derivatives.
EltrombopagCalcium Salts such as calcium acetate may decrease the serum concentration of Eltrombopag. Separate administration of eltrombopag and any polyvalent cation (e.g., calcium-containing products) by at least 4 hours.
EstramustineCalcium salts such as calcium acetate may decrease the absorption of estramustine. Interactions can be minimized by administering estramustine on an empty stomach, at least 1 hour before or 2 hours after the dose of an oral calcium supplement. Do not coadminister estramustine with food or milk. Monitor for decreased therapeutic effects of estramustine if administered with oral calcium supplements, food or milk.
Etidronic acidCalcium Salts may decrease the serum concentration of Bisphosphonate Derivatives such as etidronic acid (etidronate). Avoid administration of oral calcium supplements within 2 hours before or after tiludronate/clodronate/etidronate.
GemifloxacinCalcium salts such as calcium acetate may decrease the absorption of quinolone antibiotics such as gemifloxacin. Of concern only with oral administration of both agents. Interactions can be minimized by administering oral quinolone at least 2 hours before, or 6 hours after, the dose of an oral calcium supplement. Monitor for decreased therapeutic effects of oral quinolones if administered with oral calcium supplements.
IbandronateCalcium Salts may decrease the serum concentration of Bisphosphonate Derivatives such as ibandronate. Avoid administration of oral calcium supplements within 60 minutes after oral ibandronate.
LevofloxacinCalcium salts such as calcium acetate may decrease the absorption of quinolone antibiotics such as levofloxacin. Of concern only with oral administration of both agents. Interactions can be minimized by administering oral quinolone at least 2 hours before, or 6 hours after, the dose of an oral calcium supplement. Monitor for decreased therapeutic effects of oral quinolones if administered with oral calcium supplements.
LevothyroxineCalcium salts such as calcium acetate may diminish the therapeutic effect of thyroid products such as levothyroxine. Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours. Monitor for decreased therapeutic effects of thyroid products if an oral calcium supplement is initiated/dose increased, or increased effects if an oral calcium supplement is discontinued/dose decreased.
LiothyronineCalcium salts such as calcium acetate may diminish the therapeutic effect of thyroid products such as liothyronine. Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours. Monitor for decreased therapeutic effects of thyroid products if an oral calcium supplement is initiated/dose increased, or increased effects if an oral calcium supplement is discontinued/dose decreased.
LiotrixCalcium salts such as calcium acetate may diminish the therapeutic effect of thyroid products such as liotrix. Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours. Monitor for decreased therapeutic effects of thyroid products if an oral calcium supplement is initiated/dose increased, or increased effects if an oral calcium supplement is discontinued/dose decreased.
LomefloxacinCalcium salts such as calcium acetate may decrease the absorption of quinolone antibiotics such as lomefloxacin. Of concern only with oral administration of both agents. Interactions can be minimized by administering oral quinolone at least 2 hours before, or 6 hours after, the dose of an oral calcium supplement. Monitor for decreased therapeutic effects of oral quinolones if administered with oral calcium supplements.
MinocyclineCalcium salts such as calcium acetate may decrease the serum concentration of tetracycline derivatives such as minocycline. In general, the coadministration of oral calcium salts and oral tetracycline derivatives should be avoided. Interactions may be able to be minimized by administering oral calcium preparations several hours before or after the dose of the oral tetracycline derivatives. Even with dose separation, therapy may still be compromised. Monitor for decreased therapeutic effect of oral tetracycline derivatives.
Nalidixic AcidCalcium salts such as calcium acetate may decrease the absorption of quinolone antibiotics such as nalidixic acid. Of concern only with oral administration of both agents. Interactions can be minimized by administering oral quinolone at least 2 hours before, or 6 hours after, the dose of an oral calcium supplement. Monitor for decreased therapeutic effects of oral quinolones if administered with oral calcium supplements.
NorfloxacinCalcium salts such as calcium acetate may decrease the absorption of quinolone antibiotics such as norfloxacin. Of concern only with oral administration of both agents. Interactions can be minimized by administering oral quinolone at least 2 hours before, or 6 hours after, the dose of an oral calcium supplement. Monitor for decreased therapeutic effects of oral quinolones if administered with oral calcium supplements.
OfloxacinCalcium salts such as calcium acetate may decrease the absorption of quinolone antibiotics such as ofloxacin. Of concern only with oral administration of both agents. Interactions can be minimized by administering oral quinolone at least 2 hours before, or 6 hours after, the dose of an oral calcium supplement. Monitor for decreased therapeutic effects of oral quinolones if administered with oral calcium supplements.
RisedronateCalcium Salts may decrease the serum concentration of Bisphosphonate Derivatives such as risedronate. Avoid administration of oral calcium supplements within or 30 minutes after risedronate.
SparfloxacinCalcium salts such as calcium acetate may decrease the absorption of quinolone antibiotics such as sparfloxacin. Of concern only with oral administration of both agents. Interactions can be minimized by administering oral quinolone at least 2 hours before, or 6 hours after, the dose of an oral calcium supplement. Monitor for decreased therapeutic effects of oral quinolones if administered with oral calcium supplements.
TetracyclineCalcium salts such as calcium acetate may decrease the serum concentration of tetracycline derivatives such as tetracycline. In general, the coadministration of oral calcium salts and oral tetracycline derivatives should be avoided. Interactions may be able to be minimized by administering oral calcium preparations several hours before or after the dose of the oral tetracycline derivatives. Even with dose separation, therapy may still be compromised. Monitor for decreased therapeutic effect of oral tetracycline derivatives.
TiludronateThe divalent cation of oral Calcium Acetate may significantly decrease the absorption of Tiludronate by forming a nonabsorbable chelate. Oral dosing should be separated by at least 2 hours.
Trientine hydrochlorideCalcium salts such as calcium acetate may decrease the serum concentration of trientine. Trientine may decrease the serum concentration of Calcium Salts. The manufacturer of trientine recommends avoiding concurrent administration with mineral supplements to prevent an interaction in the gastrointestinal tract that would impair absorption of trientine. The recommendation is that trientine be taken at least one hour before or two hours after meals and at least one hour apart from any drug, food, or milk.
TrovafloxacinCalcium may decrease the absorption of orally administered Trovafloxacin. Administer Trovafloxacin 2 hours before or 6 hours after a dose of the calcium containining agent to minimize the interaction.
Food InteractionsNot Available

Targets

1. Phosphate

Kind: small molecule

Organism: Human

Pharmacological action: yes

Actions: binder

Components

Name UniProt ID Details

References:

  1. Mai ML, Emmett M, Sheikh MS, Santa Ana CA, Schiller L, Fordtran JS: Calcium acetate, an effective phosphorus binder in patients with renal failure. Kidney Int. 1989 Oct;36(4):690-5. Pubmed
  2. Nolan CR, Qunibi WY: Calcium salts in the treatment of hyperphosphatemia in hemodialysis patients. Curr Opin Nephrol Hypertens. 2003 Jul;12(4):373-9. Pubmed
  3. Nolan CR, Qunibi WY: Treatment of hyperphosphatemia in patients with chronic kidney disease on maintenance hemodialysis. Kidney Int Suppl. 2005 Jun;(95):S13-20. Pubmed
  4. Nolan CR: Phosphate binder therapy for attainment of K/DOQI bone metabolism guidelines. Kidney Int Suppl. 2005 Jul;(96):S7-14. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 16, 2013 17:08